Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com
Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report sent to investors on Tuesday morning. The firm issued a hold rating on the biotechnology company's stock.
StockNews.com 开始报道的股票 Nabriva Therapeutics（纳斯达克股票代码：NBRV — 获取评级） 在周二上午发给投资者的研究报告中。该公司对这家生物技术公司的股票发布了持有评级。
Separately, Northland Securities lowered Nabriva Therapeutics from an outperform rating to an underperform rating in a research note on Friday, January 6th.
另外，Northland Securities在1月6日星期五的一份研究报告中将Nabriva Therapeutics的评级从跑赢大盘下调至跑赢大盘。
Nabriva Therapeutics Trading Down 0.5 %
Nabriva Therapeutics下跌0.5％
Shares of NASDAQ:NBRV opened at $1.55 on Tuesday. Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $13.65. The firm has a market capitalization of $47.49 million, a price-to-earnings ratio of -0.08 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 1.40. The business's 50 day moving average price is $1.93 and its 200-day moving average price is $3.69.
纳斯达克股票代码：NBRV的股价周二开盘价为1.55美元。Nabriva Therapeutics创下1年低点1.22美元，1年来的最高水平为13.65美元。该公司的市值为4,749万美元，市盈率为-0.08，beta值为1.67。该公司的债务与权益比率为0.02，流动比率为2.20，速动比率为1.40。该公司的50天移动平均线价格为1.93美元，其200天移动平均线价格为3.69美元。
Hedge Funds Weigh In On Nabriva Therapeutics
对冲基金对 Nabriva Therapeutics 进行了权衡
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned about 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.23% of the stock is owned by hedge funds and other institutional investors.
一位机构投资者最近提高了其在Nabriva Therapeutics股票中的头寸。根据Renaissance Technologies LLC向美国证券交易委员会披露的最新信息，该公司在第二季度将其持有的Nabriva Therapeutics plc（纳斯达克股票代码：NBRV — 获取评级）的股票增加了102.1％。该基金在本季度又收购了402,144股股票后，拥有这家生物技术公司的795,938股股票。截至最近报告期末，Renaissance Technologies LLC拥有Nabriva Therapeutics约0.13％的股份，价值14.5万美元。该股0.23％由对冲基金和其他机构投资者持有。
Nabriva Therapeutics Company Profile
纳布里瓦疗法公司简介
(Get Rating)
（获取评分）
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics Plc是一家生物制药公司，从事治疗严重感染的新型抗感染药物的研究、开发和商业化。其产品线包括Lefamulin、CONTEPO 和 BC-7013。该公司成立于 2005 年 10 月，总部位于爱尔兰都柏林。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- 免费获取 StockNews.com 关于 Nabriva Therapeutics (NBRV) 的研究报告
- 埃克森美孚股票：距离买入点仅几步之遥
- 高股息收益的必和必拓认为中国将推动 “23” 的增长
- Airbnb是否准备像分析师所预测的那样上涨38％？
- 特斯拉汽车降价对TSLA股票意味着同样的吗？
- 微软裁员预示着其他科技公司的裁员？
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Nabriva Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Nabriva Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。